Mineralys director exercises options, sells 3,000 shares
Mineralys Therapeutics director Daphne Karydas exercised stock options for 3,000 shares of common stock at $12.02 per share and sold 3,000 shares at $25.00 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Mineralys Therapeutics director Daphne Karydas exercised stock options for 3,000 shares of common stock at $12.02 per share and sold 3,000 shares at $25.00 per share. After these transactions, she holds 6,200 shares directly. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025.
Insider Trade Summary 10b5-1
Exercise and Sale: 3,000 shares ($39K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Karydas Daphne
Role
Director
Sold
3,000 shs ($75K)
Approx. gross sale proceeds
$75K
Approx. exercise cost
$36K
Approx. pre-tax spread
$39K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 3,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,000 | $12.02 | $36K |
| Sale | Common Stock | 3,000 | $25.00 | $75K |
Holdings After Transaction:
Stock Option — 38,000 contracts (Direct);
Common Stock — 6,200 shares (Direct)
Footnotes (2)
- F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.
- F2. The stock option vests in 36 monthly installments beginning on October 13, 2023.
Key Figures
Shares sold: 3,000 shares
Sale price: $25.00 per share
Options exercised: 3,000 shares
+5 more
8 metrics
Shares sold
3,000 shares
Open-market sale of common stock on June 17, 2026
Sale price
$25.00 per share
Price for 3,000 Mineralys common shares sold
Options exercised
3,000 shares
Stock options converted into common shares
Exercise price
$12.02 per share
Exercise price of stock options into common stock
Shares held after
6,200 shares
Direct common stock holdings after transactions
Option expiration
September 13, 2033
Original expiration date of exercised stock option grant
10b5-1 plan adoption
December 30, 2025
Date the Rule 10b5-1 trading plan was adopted
Vesting schedule
36 monthly installments
Stock option vests monthly starting October 13, 2023
Key Terms
Rule 10b5-1 trading plan, Stock Option, derivative security, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option financial
"security_title": "Stock Option""
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
expiration date financial
"expiration_date": "2033-09-13T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Daphne Karydas report at Mineralys Therapeutics (MLYS)?
Daphne Karydas reported exercising stock options for 3,000 Mineralys Therapeutics shares and selling 3,000 common shares. These same-day transactions combined an option exercise with an open-market sale, while she retained a remaining direct holding after the trades.
At what prices did the Mineralys Therapeutics (MLYS) insider transactions occur?
Karydas exercised stock options at an exercise price of $12.02 per Mineralys share and sold 3,000 common shares at $25.00 per share. This reflects an exercise-and-sell pattern, turning option value into cash while maintaining a continuing equity position.
Were the Mineralys Therapeutics (MLYS) insider trades made under a Rule 10b5-1 plan?
Yes, the transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025. Such plans schedule trades in advance, which can make the timing of the sale appear more routine rather than discretionary.
What stock options did Daphne Karydas exercise at Mineralys Therapeutics (MLYS)?
She exercised stock options covering 3,000 underlying shares of Mineralys common stock with a stated exercise price of $12.02 per share. The option grant vests in 36 monthly installments beginning on October 13, 2023, according to the disclosure footnote.
What happens to Daphne Karydas’ stock options after the reported Mineralys (MLYS) Form 4?
The filing shows a derivative transaction for 3,000 stock options exercised into common shares, with no remaining position for that grant in the derivative summary. The options had an expiration date of September 13, 2033 before exercise.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates